Background: There are many barriers to prescribing medications for opioid use disorder (MOUD). This study evaluates the prevalence, patterns, and predictors of inpatient MOUD prescribing at discharge to patients with a diagnosis of opioid use/opioid use disorder (OUD) that developed opioid withdrawal during their hospital stay.

Methods: This multicenter, retrospective cross-sectional study occurred at three hospitals in Arizona. Patients who developed opioid withdrawal during their hospitalization and had a documented opioid-related disorder between January 1, 2021, and January 1, 2022, were included in the study. Patient-specific factors were evaluated as predictors of MOUD prescribing at hospital discharge using descriptive, multivariate regression.

Results: A total of 382 encounters were included; 249 had documented OUD (65.2 %), 75 of which were discharged with MOUD (75/249; 30.1 %). Patients with moderate/moderately severe opioid withdrawal had higher odds of being discharged with MOUD compared to those with mild opioid withdrawal (OR 2.87 [1.44-5.69], p=0.003). Patients admitted to the largest hospital in Phoenix had higher odds of being prescribed MOUD compared to the largest hospital in Tucson (OR 8.23 [3.02-22.49], p<0.001), as were patients who underwent a routine discharge compared to patient directed discharges (7.63 [2.35-24.71], p=0.001).

Conclusions: Less than one-third of patients with OUD that developed opioid withdrawal during their hospitalization were prescribed MOUD at discharge. Treatment facility, opioid withdrawal severity, and discharge disposition were predictors of MOUD prescribing. Inpatient health-systems and policymakers may consider these data when developing policies/procedures aimed at increasing MOUD prescribing rates.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11701998PMC
http://dx.doi.org/10.1016/j.dadr.2024.100292DOI Listing

Publication Analysis

Top Keywords

opioid withdrawal
16
prevalence patterns
8
patterns predictors
8
prescribing medications
8
medications opioid
8
opioid disorder
8
disorder moud
8
moud prescribing
8
developed opioid
8
discharged moud
8

Similar Publications

The current opioid crisis has had an unprecedented public health impact. Approved medications for opioid use disorder (OUD) exist, yet their limitations indicate a need for innovative treatments. Limited preliminary clinical studies suggest specific psychedelics might aid OUD treatment, though most clinical evidence remains observational, with few controlled trials.

View Article and Find Full Text PDF

Introduction: Opioid overdose mortality rates have surged dramatically in the last decade due largely to fentanyl in the illicit US drug supply. As of June 2024, 38 states, three territories, namely US Virgin Islands, Guam and the Northern Mariana Islands, and the District of Columbia, allow the medical use of cannabis products. However, there remains limited qualitative community-based evidence on the role of cannabis co-use among opioid using and injecting populations.

View Article and Find Full Text PDF

Opioids represent one of the key pillars in postoperative pain management, but their use has been associated with a variety of serious side effects. Thus, it is crucial to investigate the timing and course of opioid administration in order to ensure a best efficacy to side-effect profile. The aim of our article was to investigate the analgesic effects of locally administered morphine sulfate (intraplantar) in a carrageenan-induced inflammation model in rats.

View Article and Find Full Text PDF

Decreased opioid receptor availability and impaired neurometabolic coupling as signatures of morphine tolerance in male rats: A positron emission tomography study.

Biomed Pharmacother

January 2025

Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Université Paris-Saclay, Orsay, France. Electronic address:

Translational neuroimaging techniques are needed to address the impact of opioid tolerance on brain function and quantitatively monitor the impaired neuropharmacological response to opioids at the CNS level. A multiparametric PET study was conducted in rats. Rats received morphine daily to induce tolerance (15 mg/kg/day for 5 days), followed by 2-day withdrawal.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!